# Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass

> **NCT02086968** · PHASE4 · COMPLETED · sponsor: **American Regent, Inc.** · enrollment: 198 (actual)

## Conditions studied

- Iron Deficiency Anemia Secondary to IBD or Gastric Bypass

## Interventions

- **DRUG:** Injectafer
- **DRUG:** Ferrous Sulfate tablets

## Key facts

- **NCT ID:** NCT02086968
- **Lead sponsor:** American Regent, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-01
- **Primary completion:** 2016-07-16
- **Final completion:** 2017-10
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086968, "Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02086968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*